Jyoti D. Malhotra

Oncology

1500 Duarte Rd
Duarte, CA 91010

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 123 publications

Updates in the management of small cell lung cancer.

Updates in the management of small cell lung cancer.

Journal: Clinical advances in hematology & oncology : H&O

Published: May 07, 2026

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Journal: Cell reports. Medicine

Published: March 19, 2026

Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States.

Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States.

Journal: Advances in therapy

Published: February 24, 2026

NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.

NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Impact of Real-World Response to First-Line Immunotherapy and Chemotherapy on Subsequent Treatment Outcomes in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer.

Impact of Real-World Response to First-Line Immunotherapy and Chemotherapy on Subsequent Treatment Outcomes in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer.

Journal: JCO clinical cancer informatics

Published: January 21, 2026

Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Journal: JCO oncology practice

Published: December 15, 2025

The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy.

The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy.

Journal: Cancer cell

Published: December 08, 2025

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Journal: Cancer

Published: November 04, 2025

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.

Journal: Cancer research communications

Published: September 24, 2025

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.

Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.

Journal: Cancer research communications

Published: September 24, 2025

Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review.

Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review.

Journal: Cancers

Published: September 11, 2025

Treating EGFR-mutant nonsmall cell lung cancer is no longer a one-size-fits-all approach.

Treating EGFR-mutant nonsmall cell lung cancer is no longer a one-size-fits-all approach.

Journal: CA: a cancer journal for clinicians

Published: August 04, 2025

Showing 1-12 of 123

Last Updated: 09/26/2026